Literature DB >> 23355464

Humanization of antibodies using heavy chain complementarity-determining region 3 grafting coupled with in vitro somatic hypermutation.

Peter M Bowers1, Tamlyn Y Neben, Geoffery L Tomlinson, Jennifer L Dalton, Larry Altobell, Xue Zhang, John L Macomber, Betty F Wu, Rachelle M Toobian, Audrey D McConnell, Petra Verdino, Betty Chau, Robert A Horlick, David J King.   

Abstract

A method for simultaneous humanization and affinity maturation of monoclonal antibodies has been developed using heavy chain complementarity-determining region (CDR) 3 grafting combined with somatic hypermutation in vitro. To minimize the amount of murine antibody-derived antibody sequence used during humanization, only the CDR3 region from a murine antibody that recognizes the cytokine hβNGF was grafted into a nonhomologous human germ line V region. The resulting CDR3-grafted HC was paired with a CDR-grafted light chain, displayed on the surface of HEK293 cells, and matured using in vitro somatic hypermutation. A high affinity humanized antibody was derived that was considerably more potent than the parental antibody, possessed a low pm dissociation constant, and demonstrated potent inhibition of hβNGF activity in vitro. The resulting antibody contained half the heavy chain murine donor sequence compared with the same antibody humanized using traditional methods.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23355464      PMCID: PMC3597809          DOI: 10.1074/jbc.M112.445502

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Improving antibody affinity by mimicking somatic hypermutation in vitro.

Authors:  P S Chowdhury; I Pastan
Journal:  Nat Biotechnol       Date:  1999-06       Impact factor: 54.908

2.  In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library.

Authors:  H Gram; L A Marconi; C F Barbas; T A Collet; R A Lerner; A S Kang
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

3.  Antibody humanization using monovalent phage display.

Authors:  M Baca; L G Presta; S J O'Connor; J A Wells
Journal:  J Biol Chem       Date:  1997-04-18       Impact factor: 5.157

4.  Reshaping human antibodies: grafting an antilysozyme activity.

Authors:  M Verhoeyen; C Milstein; G Winter
Journal:  Science       Date:  1988-03-25       Impact factor: 47.728

5.  CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range.

Authors:  W P Yang; K Green; S Pinz-Sweeney; A T Briones; D R Burton; C F Barbas
Journal:  J Mol Biol       Date:  1995-12-01       Impact factor: 5.469

6.  A humanized antibody that binds to the interleukin 2 receptor.

Authors:  C Queen; W P Schneider; H E Selick; P W Payne; N F Landolfi; J F Duncan; N M Avdalovic; M Levitt; R P Junghans; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

7.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.

Authors:  S L Morrison; M J Johnson; L A Herzenberg; V T Oi
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

8.  Three distinct types of monoclonal antibodies after long-term immunization of rats with mouse nerve growth factor.

Authors:  A Cattaneo; B Rapposelli; P Calissano
Journal:  J Neurochem       Date:  1988-04       Impact factor: 5.372

9.  Selection of phage antibodies by binding affinity. Mimicking affinity maturation.

Authors:  R E Hawkins; S J Russell; G Winter
Journal:  J Mol Biol       Date:  1992-08-05       Impact factor: 5.469

10.  High affinity humanized antibodies without making hybridomas; immunization paired with mammalian cell display and in vitro somatic hypermutation.

Authors:  Audrey D McConnell; Minjee Do; Tamlyn Y Neben; Vladimir Spasojevic; Josh MacLaren; Andy P Chen; Laurence Altobell; John L Macomber; Ashley D Berkebile; Robert A Horlick; Peter M Bowers; David J King
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

View more
  9 in total

1.  Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.

Authors:  Sue Townsend; Brian J Fennell; James R Apgar; Matthew Lambert; Barry McDonnell; Joanne Grant; Jason Wade; Edward Franklin; Niall Foy; Deirdre Ní Shúilleabháin; Conor Fields; Alfredo Darmanin-Sheehan; Amy King; Janet E Paulsen; Timothy P Hickling; Lioudmila Tchistiakova; Orla Cunningham; William J J Finlay
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

2.  Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody.

Authors:  James R Apgar; Michelle Mader; Rita Agostinelli; Susan Benard; Peter Bialek; Mark Johnson; Yijie Gao; Mark Krebs; Jane Owens; Kevin Parris; Michael St Andre; Kris Svenson; Carl Morris; Lioudmila Tchistiakova
Journal:  MAbs       Date:  2016-09-13       Impact factor: 5.857

3.  Identification of high affinity HER2 binding antibodies using CHO Fab surface display.

Authors:  Annalee W Nguyen; Kevin C Le; Jennifer A Maynard
Journal:  Protein Eng Des Sel       Date:  2018-03-01       Impact factor: 1.650

4.  Generation of a high-fidelity antibody against nerve growth factor using library scanning mutagenesis and validation with structures of the initial and optimized Fab-antigen complexes.

Authors:  Sherry L La Porte; Charles Eigenbrot; Mark Ultsch; Wei-Hsien Ho; Davide Foletti; Alison Forgie; Kevin C Lindquist; David L Shelton; Jaume Pons
Journal:  MAbs       Date:  2014 Jul-Aug       Impact factor: 5.857

5.  Identifying the Epitope Regions of Therapeutic Antibodies Based on Structure Descriptors.

Authors: 
Journal:  Int J Mol Sci       Date:  2017-11-24       Impact factor: 5.923

6.  Design and Construction of a Novel Humanized Single-Chain Variable-Fragment Antibody Against the Tumor Necrosis Factor Alpha.

Authors:  Davoud Farajzadeh; Sadigheh Karimi-Gharigh; Parisa Jalali-Kondori; Siavoush Dastmalchi
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

Review 7.  Dostarlimab: A Review.

Authors:  Bárbara Costa; Nuno Vale
Journal:  Biomolecules       Date:  2022-07-26

8.  Mimicking the germinal center reaction in hybridoma cells to isolate temperature-selective anti-PEG antibodies.

Authors:  Yu-Cheng Su; Talal S Al-Qaisi; Hsin-Yi Tung; Tian-Lu Cheng; Kuo-Hsiang Chuang; Bing-Mae Chen; Steve R Roffler
Journal:  MAbs       Date:  2014-05-14       Impact factor: 5.857

9.  Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma.

Authors:  Yi-Fan Zhang; Mitchell Ho
Journal:  Sci Rep       Date:  2016-09-26       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.